SAN FRANCISCO--(BUSINESS WIRE)--Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, today announced the successful completion of a $43 million Series A financing round. The round was led by existing investor Andreessen Horowitz (a16z Bio + Health), with participation from Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV, Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels and ExitFund..

旧金山--（商业新闻短讯）--Arda Therapeutics是慢性病靶向细胞耗竭疗法的先驱，今天宣布成功完成4300万美元的a系列融资。本轮投资由现有投资者Andreessen Horowitz（a16z Bio+Health）牵头，两西格玛风险投资公司（Two Sigma Ventures）、RV Invest、礼来公司（Eli Lilly and Company）、GV、Biovision Ventures、Valhalla Ventures、Indicator Ventures、Alumban Ventures、LifeLink Ventures、Mana Ventures、Gaingels和ExitFund等公司。

For decades, the dominant approach in drug development has been to modulate individual proteins and signaling pathways to ameliorate disease. While this strategy has yielded some success, it often leads to limited efficacy and incremental gains, particularly for complex chronic diseases. Arda Therapeutics is pursuing a novel alternative by depleting the cells that drive disease rather than modulating the activity of the proteins they produce..

几十年来，药物开发的主要方法是调节单个蛋白质和信号通路以改善疾病。虽然这一策略取得了一些成功，但它通常会导致有限的疗效和增量收益，特别是对于复杂的慢性疾病。

“Arda is at the forefront of a paradigm shift in treating chronic diseases,” said Adam Freund, Ph.D., founder and CEO of Arda Therapeutics. “By focusing on the cells at the core of disease, we can develop therapies that are not only more effective, but also have the potential to fundamentally change patient outcomes.

Arda Therapeutics创始人兼首席执行官AdamFreund博士说：“Arda处于治疗慢性病范式转变的前沿。”。“通过关注疾病核心的细胞，我们可以开发出不仅更有效，而且有可能从根本上改变患者预后的疗法。

With drug approval rates declining and efficacy improvements stalling, Arda’s strategy to target cells—not pathways—offers a transformative shift in how chronic diseases are treated. With the support of our Series A investors, Arda is well positioned to progress our lead programs toward the clinic and expand our platform to tackle even more disease areas.”.

随着药物批准率下降和疗效改善停滞，Arda针对细胞而非途径的策略为慢性病的治疗方式提供了革命性的转变。在我们的A系列投资者的支持下，Arda处于有利地位，可以将我们的领先项目推向诊所，并扩展我们的平台，以应对更多的疾病领域。”

Arda’s sophisticated single-cell-based discovery engine identifies the specific pathogenic cells responsible for disease and their surface markers with unprecedented precision. This approach enables the development of targeted biologics that selectively eliminate harmful cells while preserving healthy tissue, leading to significantly greater efficacy and fewer side effects compared to conventional treatments.

Arda先进的基于单细胞的发现引擎以前所未有的精度识别出导致疾病的特定致病细胞及其表面标记。这种方法能够开发靶向生物制剂，选择性地消除有害细胞，同时保存健康组织，与常规治疗相比，产生显着更高的功效和更少的副作用。

Arda’s platform has broad applicability across a wide range of diseases, including fibrotic conditions such as pulmonary fibrosis, as well as autoimmune and metabolic disorders..

Arda的平台在广泛的疾病中具有广泛的适用性，包括肺纤维化等纤维化疾病，以及自身免疫和代谢紊乱。

'The field of oncology therapeutics has been focused on tumor cell clearance as a mechanism of action for decades. Many of our most potent cancer medicines - chemotherapy, CAR-T cells, antibody drug conjugates, T cell engagers, radiopharmaceuticals - fundamentally depend on our ability to identify pathogenic, or bad actor, cell populations and then target them precisely for killing,' said Vineeta Agarwala, M.D., Ph.D., general partner at Andreessen Horowitz.

“几十年来，肿瘤治疗领域一直将肿瘤细胞清除作为一种作用机制。安德烈森·霍洛维茨（AndreessenHorowitz）的普通合伙人、医学博士维尼塔·阿加瓦拉（VineetaAgarwala）说，我们许多最有效的癌症药物——化疗、CAR-T细胞、抗体-药物偶联物、T细胞接受者、放射性药物——从根本上取决于我们识别致病或不良因素细胞群的能力，然后精确地将其靶向杀伤。

'Arda is taking the ‘oncology toolbox’ outside of oncology. Applying the lessons learned from oncology, the Arda team is leveraging cutting-edge, single-cell biology and a deep understanding of the biology of diseases outside cancer to boldly extend the cell clearance paradigm to the treatment of chronic diseases.'.

Arda正在肿瘤学之外使用“肿瘤学工具箱”。应用肿瘤学的经验教训，Arda团队正在利用尖端的单细胞生物学和对癌症以外疾病生物学的深入了解，大胆地将细胞清除范式扩展到慢性疾病的治疗。”

Scott Turner, Ph.D., appointed to Chief Scientific Officer

斯科特·特纳博士被任命为首席科学官

In addition to the financing, Arda announced the appointment of Scott Turner, Ph.D., as chief scientific officer. Scott joins Arda after serving as chief scientific officer of Pliant Therapeutics, where he led the creation of the company’s fibrosis discovery platform and biomarker research, culminating in a successful Phase 2a study for Bexotegrast, an anti-fibrotic therapy.

除了资金之外，Arda还宣布任命斯科特·特纳博士为首席科学官。Scott在担任Pliant Therapeutics首席科学官后加入Arda，在那里他领导创建了该公司的纤维化发现平台和生物标志物研究，最终成功完成了抗纤维化疗法Bexotegrast的2a期研究。

At Pliant, Scott promoted the use of single-cell data to dissect drug mechanisms of action and played a critical role in developing innovative fibrosis models and biomarker strategies that advanced several clinical programs. His leadership helped secure over $500 million in financing, including an IPO.

在Pliant，Scott促进了单细胞数据的使用，以剖析药物的作用机制，并在开发创新的纤维化模型和生物标志物策略方面发挥了关键作用，从而推进了多项临床计划。他的领导帮助获得了超过5亿美元的融资，包括首次公开募股。

Scott received a B.A. from UC Santa Cruz and a Ph.D. from UC Berkeley..

斯科特获得了加州大学圣克鲁斯分校的学士学位和加州大学伯克利分校的博士学位。

“I’m thrilled to be joining Arda at such an exciting time,” said Dr. Turner. “The team has built an impressive platform for targeting pathogenic cells with precision, which holds tremendous potential for addressing the unmet needs in chronic disease. I look forward to working closely with the team to advance our lead programs toward the clinic and develop innovative therapies that can make a meaningful impact on patients’ lives.”.

特纳博士说：“我很高兴能在如此激动人心的时刻加入Arda。”。“该团队已经建立了一个令人印象深刻的平台，可以精确地靶向致病细胞，这在解决慢性病未满足的需求方面具有巨大潜力。我期待着与该团队密切合作，推动我们的领先项目走向临床，并开发创新疗法，可以对患者的生活产生有意义的影响。”。

“We are very excited to have Scott on the team,” said Rèmi Laberge, Ph.D., co-founder and chief technology officer of Arda. “His deep expertise in fibrosis drug discovery will be instrumental as we drive our programs forward. I look forward to collaborating with him to push the capabilities of our cell depletion platform to the next level.”.

Arda联合创始人兼首席技术官Rèmi Laberge博士说：“我们很高兴斯科特能加入我们的团队。”。“他在纤维化药物发现方面的深厚专业知识将有助于我们推动我们的项目向前发展。我期待着与他合作，将我们的细胞耗竭平台的能力推向一个新的水平。”

About Arda Therapeutics

关于Arda Therapeutics

Arda Therapeutics is pioneering the use of targeted cell depletion to treat chronic diseases. By identifying and selectively depleting pathogenic cells, Arda aims to develop therapies that offer greater efficacy, faster discovery timelines and reduced dosing frequency compared to traditional approaches.

Arda Therapeutics率先使用靶向细胞耗竭来治疗慢性疾病。通过鉴定和选择性消耗致病细胞，Arda旨在开发与传统方法相比具有更高功效，更快发现时间表和减少给药频率的疗法。

With a world-class team and a robust pipeline, Arda is poised to transform the landscape of chronic disease treatment. For more information, visit www.ardatx.com..

。有关更多信息，请访问www.ardatx.com。